These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35158439)

  • 41. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
    Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can reactogenicity predict immunogenicity after COVID-19 vaccination?
    Hwang YH; Song KH; Choi Y; Go S; Choi SJ; Jung J; Kang CK; Choe PG; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2021 Nov; 36(6):1486-1491. PubMed ID: 34038996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.
    Nasuelli NA; De Marchi F; Cecchin M; De Paoli I; Onorato S; Pettinaroli R; Savoini G; Godi L
    Neurol Sci; 2021 Nov; 42(11):4747-4749. PubMed ID: 34272622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolated thrombosis after COVID-19 vaccination: case series.
    Al-Ahmad M; Al Rasheed M; Altourah L; Rodriguez-Bouza T; Shalaby N
    Int J Hematol; 2022 Feb; 115(2):153-157. PubMed ID: 34993889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Salama S; Giovannoni G; Hawkes CH; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2020 Jul; 42():102259. PubMed ID: 32571580
    [No Abstract]   [Full Text] [Related]  

  • 49. A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
    Kim G; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH
    J Korean Med Sci; 2021 Nov; 36(43):e306. PubMed ID: 34751013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination.
    Spataro R; Fisco G; La Bella V
    BMJ Case Rep; 2022 Feb; 15(2):. PubMed ID: 35110289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting.
    Luetic GG; Menichini ML; Fernández Ó
    Mult Scler Relat Disord; 2021 Sep; 54():103148. PubMed ID: 34280680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Creed MA; Ballesteros E; Jr LJG; Imitola J
    Mult Scler Relat Disord; 2020 Sep; 44():102199. PubMed ID: 32554285
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A case report of ChAdOx1 nCoV-19 vaccine-associated encephalitis.
    Takata J; Durkin SM; Wong S; Zandi MS; Swanton JK; Corrah TW
    BMC Neurol; 2021 Dec; 21(1):485. PubMed ID: 34903200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis.
    Matthews L; Kolind S; Brazier A; Leite MI; Brooks J; Traboulsee A; Jenkinson M; Johansen-Berg H; Palace J
    PLoS One; 2015; 10(9):e0137715. PubMed ID: 26381510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report.
    de Ruijter NS; Kramer G; Gons RAR; Hengstman GJD
    Mult Scler Relat Disord; 2020 Nov; 46():102474. PubMed ID: 32892062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder.
    Combes AJE; Matthews L; Lee JS; Li DKB; Carruthers R; Traboulsee AL; Barker GJ; Palace J; Kolind S
    Neuroimage Clin; 2017; 16():17-22. PubMed ID: 28725551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse.
    Farber RS; Gross R; Zakin E; Fabian M
    Mult Scler; 2017 Jun; 23(7):988-994. PubMed ID: 27672136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].
    Nakamura M; Nakashima I
    Brain Nerve; 2020 Oct; 72(10):1079-1083. PubMed ID: 33051396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Hyun JW; Park G; Kwak K; Jo HJ; Joung A; Kim JH; Lee SH; Kim S; Lee JM; Kim SH; Kim HJ
    Eur J Neurol; 2017 Feb; 24(2):437-445. PubMed ID: 28009104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.